May 07, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation by the US FDA, Marking Another Milestone in Its Development
May 04, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia
Dec 10, 2019
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
Nov 14, 2019
Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
Oct 02, 2019
Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test
Jul 21, 2019
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
Dec 03, 2018
Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting
Nov 21, 2018
Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting
Sep 04, 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
Mar 22, 2018
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Feb 16, 2018
Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline
Dec 22, 2017
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
Dec 22, 2017
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
Nov 28, 2017
Chronic Myelogenous Leukemia Treatment Market Value to Reach US$ 8,550.8 Million by the end of 2026: Transparency Market Research
Sep 29, 2017
Mylan Launches Generic Gleevec® Tablets